(Q36090532)

English

Preclinical and clinical experience with fulvestrant (Faslodex) in postmenopausal women with hormone receptor-positive advanced breast cancer

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

1 reference

Europe PubMed Central

Preclinical and clinical experience with fulvestrant (Faslodex) in postmenopausal women with hormone receptor-positive advanced breast cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

author name string

Nigel Bundred

1

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

publication date

1 January 2005

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

Cancer Investigation

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

23

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

173-181

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database.

1 reference

https://api.crossref.org/works/10.1081%2FCNV-50480

21 January 2018

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

https://api.crossref.org/works/10.1081%2FCNV-50480

21 January 2018

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

1 reference

https://api.crossref.org/works/10.1081%2FCNV-50480

21 January 2018

Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer.

1 reference

https://api.crossref.org/works/10.1081%2FCNV-50480

21 January 2018

Toremifene and tamoxifen in advanced breast cancer--a double-blind cross-over trial.

1 reference

https://api.crossref.org/works/10.1081%2FCNV-50480

21 January 2018

Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma

1 reference

https://api.crossref.org/works/10.1081%2FCNV-50480

21 January 2018

Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group

1 reference

https://api.crossref.org/works/10.1081%2FCNV-50480

21 January 2018

Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: results of an Italian cooperative study

1 reference

https://api.crossref.org/works/10.1081%2FCNV-50480

21 January 2018

Similarities and distinctions in the mode of action of different classes of antioestrogens

1 reference

https://api.crossref.org/works/10.1081%2FCNV-50480

21 January 2018

Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1081%2FCNV-50480

21 January 2018

Equivalent single-dose pharmacokinetics of two different dosing methods of prolonged-release fulvestrant ('Faslodex') in postmenopausal women with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1081%2FCNV-50480

21 January 2018

Pharmacokinetic profile of intramuscular fulvestrant in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1081%2FCNV-50480

21 January 2018

Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment

1 reference

https://api.crossref.org/works/10.1081%2FCNV-50480

21 January 2018

Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial

1 reference

https://api.crossref.org/works/10.1081%2FCNV-50480

21 January 2018

Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials

1 reference

https://api.crossref.org/works/10.1081%2FCNV-50480

21 January 2018

Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial

1 reference

https://api.crossref.org/works/10.1081%2FCNV-50480

21 January 2018

Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapy

1 reference

https://api.crossref.org/works/10.1081%2FCNV-50480

21 January 2018

Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex).

1 reference

https://api.crossref.org/works/10.1081%2FCNV-50480

21 January 2018

Identifiers

10.1081/CNV-50480

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

release_ou4womdccrdvvhmmuwtngtmv5i

1 reference

https://api.fatcat.wiki/v0/release/ou4womdccrdvvhmmuwtngtmv5i

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36090532&oldid=1961438846"